Pancreatic cancer

A021602

RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)

Trial overview

Topic

A021602

Disease

Pancreas

Description

Primary Objective: To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic NET whose disease has progressed after prior therapy.

Contact

Florida

Peggy Mouradian

Physicians

Edgardo Santos

MD

Medical Oncologist

Aventura (Medical oncology)